Longitude Capital

Longitude Capital is a healthcare venture capital firm founded in 2006 that invests in biotechnology, medical technology and health solutions companies. The firm operates across both private and public markets, targeting businesses at clinical and commercial stages that aim to improve clinical outcomes, enhance patient quality of life and reduce the cost of care. Its stated objective is investment in companies with the potential to deliver measurable benefit on at least one of those three measures.

The firm has raised more than $2 billion across six funds since inception. Beyond traditional venture capital, Longitude Capital deploys a range of investment structures - asset spin-outs, recapitalisations, PIPEs (private investments in public equity), open-market purchases, royalties and equity-linked instruments - allowing it to take positions across the capital structure and at points in a company's lifecycle that conventional venture funds often cannot. That flexibility is a distinguishing feature of the firm's approach in a sector where clinical timelines and financing needs vary widely.

Longitude Capital maintains offices in Menlo Park, California and Boston, Massachusetts. The investment team reports combined life sciences investing experience of more than 200 years. Founders Juliet Bakker and Patrick Enright previously invested together at Pequot Ventures.

Portfolio engagement is described as hands-on, with support focused on strategic planning, operating objectives, team building, fundraising and liquidity opportunities. The firm's stated aim in working with management teams and investment partners is to help portfolio companies reach clinical and commercial milestones and to structure liquidity outcomes.